Almirall/Forest: good PhIII in COPD; pivotal data soon
This article was originally published in Scrip
Executive Summary
Almirall and Forest Laboratories are gearing up to fight for a greater share of the crowded chronic obstructive pulmonary disease COPD market as they announced positive top-line Phase III data for a fixed dose combination (FDC) of a long-acting inhaled antimuscarinic agent (LAMA), aclidinium bromide and the long-acting beta-2-adrenergic agonist (LABA) formoterol fumarate. US and EU filings will take place following the completion of another trial, for which results are expected in the 'coming weeks'.